WO2023113744A2 - A tablet formulation comprising micronized benidipine - Google Patents

A tablet formulation comprising micronized benidipine Download PDF

Info

Publication number
WO2023113744A2
WO2023113744A2 PCT/TR2022/051468 TR2022051468W WO2023113744A2 WO 2023113744 A2 WO2023113744 A2 WO 2023113744A2 TR 2022051468 W TR2022051468 W TR 2022051468W WO 2023113744 A2 WO2023113744 A2 WO 2023113744A2
Authority
WO
WIPO (PCT)
Prior art keywords
film coated
coated tablet
benidipine
sodium
tablet according
Prior art date
Application number
PCT/TR2022/051468
Other languages
French (fr)
Other versions
WO2023113744A3 (en
Inventor
Tolga GULER
Nur PEHLIVAN AKALIN
Fatih Sunel
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2021/019695 external-priority patent/TR2021019695A2/en
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2023113744A2 publication Critical patent/WO2023113744A2/en
Publication of WO2023113744A3 publication Critical patent/WO2023113744A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Definitions

  • the present invention relates to a film coated tablet formulation comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein benidipine has a d (0.9) particle size less than 50 pm. Furthermore, the formulation is obtained using an effective process.
  • Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine- dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions. It is a triple L-, T-, and N-type calcium channel blocker. The only calcium antagonist that can inhibit all the three Ca channels mentioned. Furthermore, benidipine has highly affinity with cell membrane, has vascular selectivity and renal protection effect. Therefore, it is an ideal, safe and effective agent for the treatment of hypertension and renal parenchymal hypertension and angina. Benidipine has the following chemical structure of Formula I.
  • Benidipine is a class II drug in the BCS classification, that is, poorly water soluble. For poorly soluble drugs, its dissolution is the rate-limiting process of absorption, and is often the most important factor affecting its bioavailability. It is very soluble in formic acid, freely soluble in dimethylformamide, soluble in methanol or ethanol, slightly soluble in acetic anhydride. Furthermore, benidipine HCI presents in low amounts in the formulation so, excessive use of excipients and incompatibilities between them can adversely affect compressibility. The problem can cause also flowability and content uniformity. Benidipine was originally disclosed with the application EP63365 B2.
  • a film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts having has a d (0.9) particle size less than 50 pm is provided. Also, the tablet has been developed by using standard techniques which is simple and cost-effective method.
  • the main object of the present invention is to eliminate problems caused by benidipine and bringing additional advantages to the relevant prior art.
  • Another object of the present invention is to a film coated tablet comprising benidipine has a d (0.9) particle size less than 50 pm and at least one pharmaceutically acceptable excipient in a formulation providing the desired dissolution profile.
  • Another object of the present invention is to provide a formulation which is characterized by excellent pharmacotechnical properties, such as flowability, compressibility and content uniformity.
  • Another object of the present invention is to obtain an effective process for the preparation of a film coated tablet formulation comprising benidipine which has the desired dissolution and the desired stability.
  • benidipine in the form of the free base or in the form of pharmaceutically acceptable salts having the following particle sizes is important for formulation. Especially, it positively affects the dissolution properties.
  • the obtained tablets have the desired dissolution profile.
  • particle size means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis).
  • d (0.9) means, the size at which 90% by volume of the particles are finer.
  • d (0.5) means, the size at which 50% by volume of the particles are finer.
  • a film coated tablet comprises benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein benidipine has a d (0.9) particle size less than 50 pm.
  • benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.9) particle size less than 35 pm, preferably less than 25 pm, preferably less than 18 pm.
  • benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.9) particle size between 3 pm and 18 pm.
  • benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size less than 30 pm, preferably less than 25 pm, preferably less than 20 pm, preferably less than 15 pm, preferably less than 10 pm.
  • benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size between 1 pm and 10 pm.
  • benidipine is in the form of is present as benidipine hydrochloride.
  • the amount of benidipine hydrochloride is between 1.0% and 10.0% by weight in the total formulation. Preferably, it is between 1.0% and 6.0% by weight in the total formulation.
  • a film coated tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants/glidants, coating agents or mixtures.
  • Benidipine HCI presents in low amounts in the formulation so, excessive use of excipients and incompatibilities between them can adversely affect compressibility.
  • the problem can cause also flowability and content uniformity. It was surprisingly found that when prepared the film coated tablet with at least one suitable filler, it was observed that the desired flowability, compressibility and content uniformity.
  • Suitable fillers are selected from the group comprising lactose monohydrate, microcrystalline cellulose, lactose, mannitol, spray-dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • the filler is lactose monohydrate.
  • the amount of fillers is between 70.0% and 88.0% by weight in the total formulation. Preferably, it is between 74.0% and 85.0% or between 77.0% and 83.0% by weight in the total formulation.
  • the amount provides the desired flowability, compressibility and content uniformity.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, alginate, alginic acid, xanthan gum, hyaluronic acid, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the binder is polyvinylpyrrolidone.
  • the amount of binders is between 2.0% and 15.0% by weight in the total formulation. Preferably, it is between 2.5% and 10.0% or between 3.0% and 8.0% by weight in the total formulation.
  • Suitable disintegrants are selected from the group comprising pregelatinized starch, crospovidone, croscarmellose sodium, starch, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, low substituted hydroxypropyl cellulose, sodium alginate, corn starch, sodium starch glycolate, sodium glycine carbonate or mixtures thereof.
  • the disintegrant is pregelatinized starch.
  • the amount of disintegrants is between 3.0% and 15.0% by weight in the total formulation. Preferably, it is between 5.0% and 12.0% or between 6.0% and 10.0% by weight in the total formulation.
  • Suitable lubricants/glidants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, talc, colloidal silicon dioxide, corn, calcium stearate, zinc stearate, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fumaric acid, glyceryl palmito sulphate or mixtures thereof.
  • the lubricant/glidant is magnesium stearate.
  • the amount of lubricant/glidant is between 0.1% and 3.0% by weight in the total formulation. Preferably, it is between 0.5% and 2.0% by weight in the total formulation.
  • Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, talc, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerine, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), ponceau, iron oxides, pigments, dyes, titanium dioxide, triacetin, coloring agent or mixtures thereof.
  • the coating agents are hydroxypropyl methylcellulose, talc, titanium dioxide, polyethylene glycol.
  • the coating agents are lactose monohydrate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, yellow iron oxide, triacetin, ponceau, FD&C Blue.
  • the amount of coating agents is 1.0% to 5.0% by weight by weight in the total formulation.
  • the film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a hardness of between 20 N and 70 N. This provides high chemical and mechanical stability, thus it is not brittle easily, but also provides a high dissolution rate and short disintegration time.
  • the film coated tablet comprises;
  • the film coated tablet comprises;
  • the film coated tablet is obtained by using a wet granulation method therefore, a simple and low-cost production method was employed.
  • Wet granulation process efficiently counteracts segregation, so it can achieve good dissolution and disintegration properties.
  • a granulation solution is prepared with at least one binder and a solvent (preferably water), it was observed that the desired content uniformity is provided.
  • a solvent preferably water
  • a process for the preparation of the film coated tablet comprising benidipine comprises the following steps: a) Mixing benidipine hydrochloride having d90 particle size less than 50 pm, at least one filler and at least one disintegrant and then sieving, b) Dissolving at least one binder in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding at least one lubricant/glidant and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.
  • a process for the preparation of the film coated tablet comprising benidipine comprises the following steps: a) Mixing benidipine hydrochloride, lactose monohydrate and pregelatinized starch and then sieving, b) Dissolving polyvinylpyrrolidone in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding magnesium stearate and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.
  • Example 1 Film coating tablet
  • Example 2 Film coating tablet
  • Example 3 Film coating tablet
  • a process for example 1 or 2 or 3 a) Mixing benidipine hydrochloride, lactose monohydrate and pregelatinized starch and then sieving, b) Dissolving polyvinylpyrrolidone in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding magnesium stearate and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.

Abstract

The present invention relates to a film coated tablet formulation comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein benidipine has a d (0.9) particle size less than 50 µm. Furthermore, the formulation is obtained using an effective process.

Description

A TABLET FORMULATION COMPRISING MICRONIZED BENIDIPINE
Field of the Invention
The present invention relates to a film coated tablet formulation comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein benidipine has a d (0.9) particle size less than 50 pm. Furthermore, the formulation is obtained using an effective process.
Background of the Invention
Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine- dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride. It is a synthetic dihydropyridine derivative that has anti-hypertensive and anti-anginal actions. It is a triple L-, T-, and N-type calcium channel blocker. The only calcium antagonist that can inhibit all the three Ca channels mentioned. Furthermore, benidipine has highly affinity with cell membrane, has vascular selectivity and renal protection effect. Therefore, it is an ideal, safe and effective agent for the treatment of hypertension and renal parenchymal hypertension and angina. Benidipine has the following chemical structure of Formula I.
Figure imgf000002_0001
Formula I: Benidipine
Benidipine is a class II drug in the BCS classification, that is, poorly water soluble. For poorly soluble drugs, its dissolution is the rate-limiting process of absorption, and is often the most important factor affecting its bioavailability. It is very soluble in formic acid, freely soluble in dimethylformamide, soluble in methanol or ethanol, slightly soluble in acetic anhydride. Furthermore, benidipine HCI presents in low amounts in the formulation so, excessive use of excipients and incompatibilities between them can adversely affect compressibility. The problem can cause also flowability and content uniformity. Benidipine was originally disclosed with the application EP63365 B2.
In this invention, to overcome these problems mentioned above, a film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts having has a d (0.9) particle size less than 50 pm is provided. Also, the tablet has been developed by using standard techniques which is simple and cost-effective method.
Detailed Description of the Invention
The main object of the present invention is to eliminate problems caused by benidipine and bringing additional advantages to the relevant prior art.
Another object of the present invention is to a film coated tablet comprising benidipine has a d (0.9) particle size less than 50 pm and at least one pharmaceutically acceptable excipient in a formulation providing the desired dissolution profile.
Another object of the present invention is to provide a formulation which is characterized by excellent pharmacotechnical properties, such as flowability, compressibility and content uniformity.
Another object of the present invention is to obtain an effective process for the preparation of a film coated tablet formulation comprising benidipine which has the desired dissolution and the desired stability.
We have found that benidipine in the form of the free base or in the form of pharmaceutically acceptable salts having the following particle sizes is important for formulation. Especially, it positively affects the dissolution properties. The obtained tablets have the desired dissolution profile.
As used here in, ‘particle size’ means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis). The term d (0.9) means, the size at which 90% by volume of the particles are finer. The term d (0.5) means, the size at which 50% by volume of the particles are finer.
According to one embodiment of the invention, a film coated tablet comprises benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein benidipine has a d (0.9) particle size less than 50 pm. According to this embodiment of the present invention, benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.9) particle size less than 35 pm, preferably less than 25 pm, preferably less than 18 pm.
According to this embodiment of the present invention, benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.9) particle size between 3 pm and 18 pm.
According to this embodiment of the present invention, benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size less than 30 pm, preferably less than 25 pm, preferably less than 20 pm, preferably less than 15 pm, preferably less than 10 pm.
According to this embodiment of the present invention, benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a d (0.5) particle size between 1 pm and 10 pm.
According to this embodiment of the present invention, benidipine is in the form of is present as benidipine hydrochloride.
According to one embodiment of the present invention, the amount of benidipine hydrochloride is between 1.0% and 10.0% by weight in the total formulation. Preferably, it is between 1.0% and 6.0% by weight in the total formulation.
According to one embodiment of the invention, a film coated tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants/glidants, coating agents or mixtures.
Benidipine HCI presents in low amounts in the formulation so, excessive use of excipients and incompatibilities between them can adversely affect compressibility. The problem can cause also flowability and content uniformity. It was surprisingly found that when prepared the film coated tablet with at least one suitable filler, it was observed that the desired flowability, compressibility and content uniformity.
Suitable fillers are selected from the group comprising lactose monohydrate, microcrystalline cellulose, lactose, mannitol, spray-dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof. According to one embodiment of the present invention, the filler is lactose monohydrate.
According to one embodiment of the present invention, the amount of fillers is between 70.0% and 88.0% by weight in the total formulation. Preferably, it is between 74.0% and 85.0% or between 77.0% and 83.0% by weight in the total formulation. The amount provides the desired flowability, compressibility and content uniformity.
Suitable binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, alginate, alginic acid, xanthan gum, hyaluronic acid, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
According to one embodiment of the present invention, the binder is polyvinylpyrrolidone.
According to one embodiment of the present invention, the amount of binders is between 2.0% and 15.0% by weight in the total formulation. Preferably, it is between 2.5% and 10.0% or between 3.0% and 8.0% by weight in the total formulation.
Suitable disintegrants are selected from the group comprising pregelatinized starch, crospovidone, croscarmellose sodium, starch, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, low substituted hydroxypropyl cellulose, sodium alginate, corn starch, sodium starch glycolate, sodium glycine carbonate or mixtures thereof.
According to one embodiment of the present invention, the disintegrant is pregelatinized starch.
According to one embodiment of the present invention, the amount of disintegrants is between 3.0% and 15.0% by weight in the total formulation. Preferably, it is between 5.0% and 12.0% or between 6.0% and 10.0% by weight in the total formulation.
Suitable lubricants/glidants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, talc, colloidal silicon dioxide, corn, calcium stearate, zinc stearate, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fumaric acid, glyceryl palmito sulphate or mixtures thereof. According to one embodiment of the present invention, the lubricant/glidant is magnesium stearate.
According to one embodiment of the present invention, the amount of lubricant/glidant is between 0.1% and 3.0% by weight in the total formulation. Preferably, it is between 0.5% and 2.0% by weight in the total formulation.
Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, talc, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerine, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), ponceau, iron oxides, pigments, dyes, titanium dioxide, triacetin, coloring agent or mixtures thereof.
According to an embodiment of the present invention, the coating agents are hydroxypropyl methylcellulose, talc, titanium dioxide, polyethylene glycol.
According to an embodiment of the present invention, the coating agents are lactose monohydrate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, yellow iron oxide, triacetin, ponceau, FD&C Blue.
According to an embodiment of the present invention, the amount of coating agents is 1.0% to 5.0% by weight by weight in the total formulation.
According to one embodiment of the present invention, the film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a hardness of between 20 N and 70 N. This provides high chemical and mechanical stability, thus it is not brittle easily, but also provides a high dissolution rate and short disintegration time.
Hardness test was done with Erweka Tablet Hardness Tester.
According to one embodiment of the present invention, the film coated tablet comprises;
- Benidipine hydrochloride having d90 particle size less than 50 pm
- Lactose monohydrate
- Polyvinylpyrrolidone According to one embodiment of the present invention, the film coated tablet comprises;
- Benidipine hydrochloride having d90 particle size less than 50 pm
- Lactose monohydrate
- Pregelatinized starch
- Polyvinylpyrrolidone
- Magnesium stearate
According to one embodiment of the present invention, the film coated tablet is obtained by using a wet granulation method therefore, a simple and low-cost production method was employed. Wet granulation process efficiently counteracts segregation, so it can achieve good dissolution and disintegration properties. In the process, when a granulation solution is prepared with at least one binder and a solvent (preferably water), it was observed that the desired content uniformity is provided. Especially, the problem caused by the use of small amounts of benidipine has been prevented by the wet granulation comprising suitable excipients and steps.
According to one embodiment of the present invention, a process for the preparation of the film coated tablet comprising benidipine comprises the following steps: a) Mixing benidipine hydrochloride having d90 particle size less than 50 pm, at least one filler and at least one disintegrant and then sieving, b) Dissolving at least one binder in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding at least one lubricant/glidant and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.
According to one embodiment of the present invention, a process for the preparation of the film coated tablet comprising benidipine comprises the following steps: a) Mixing benidipine hydrochloride, lactose monohydrate and pregelatinized starch and then sieving, b) Dissolving polyvinylpyrrolidone in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding magnesium stearate and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.
Example 1 : Film coating tablet
Figure imgf000008_0001
Example 2: Film coating tablet
Figure imgf000008_0002
Example 3: Film coating tablet
Figure imgf000009_0001
A process for example 1 or 2 or 3; a) Mixing benidipine hydrochloride, lactose monohydrate and pregelatinized starch and then sieving, b) Dissolving polyvinylpyrrolidone in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding magnesium stearate and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.

Claims

9 CLAIMS
1. A film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, wherein benidipine has a d (0.9) particle size less than 50 pm.
2. The film coated tablet according to claim 1 , wherein the amount of benidipine hydrochloride is between 1.0% and 10.0% by weight in the total formulation.
3. The film coated tablet according to claim 1, wherein benidipine is in the form of is present as benidipine hydrochloride.
4. The film coated tablet according to claim 1, wherein at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, binders, disintegrants, lubricants/glidants, coating agents or mixtures.
5. The film coated tablet according to claim 4, wherein fillers are selected from the group comprising lactose monohydrate, microcrystalline cellulose, lactose, mannitol, spray- dried mannitol, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
6. The film coated tablet according to claim 5, wherein the filler is lactose monohydrate.
7. The film coated tablet according to claim 5, wherein the amount of fillers is between 70.0% and 88.0% by weight in the total formulation.
8. The film coated tablet according to claim 4, wherein binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, alginate, alginic acid, xanthan gum, hyaluronic acid, polysaccharides, carbomer, poloxamer, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
9. The film coated tablet according to claim 8, wherein the binder is polyvinylpyrrolidone. The film coated tablet according to claim 4, wherein disintegrants are selected from the group comprising pregelatinized starch, crospovidone, croscarmellose sodium, starch, low-substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, low substituted hydroxypropyl cellulose, sodium alginate, corn starch, sodium starch glycolate, sodium glycine carbonate or mixtures thereof. The film coated tablet according to claim 10, wherein the disintegrant is pregelatinized starch. The film coated tablet according to claim 1, wherein the film coated tablet comprising benidipine in the form of the free base or in the form of pharmaceutically acceptable salts has a hardness of between 20 N and 70 N. The film coated tablet according to claim 1, wherein the film coated tablet comprising;
- Benidipine hydrochloride having d90 particle size less than 50 pm
- Lactose monohydrate
- Polyvinylpyrrolidone The film coated tablet according to claim 1 , wherein the film coated tablet comprising;
- Benidipine hydrochloride having d90 particle size less than 50 pm
- Lactose monohydrate
- Pregelatinized starch
- Polyvinylpyrrolidone
- Magnesium stearate A process for the preparation of the film coated tablet comprising benidipine comprises the following steps: a) Mixing benidipine hydrochloride having d90 particle size less than 50 pm, at least one filler and at least one disintegrant and then sieving, b) Dissolving at least one binder in water, c) Granulating the mixture at step (a) with the granulation solution at step (b), d) Sieving the wet granule and drying the wet granule at fluid bed dryer, e) Sieving the dry granule, f) Adding at least one lubricant/glidant and then mixing, g) Compressing the prepared mixture to form tablets h) Coating these tablets with coating agents.
PCT/TR2022/051468 2021-12-13 2022-12-10 A tablet formulation comprising micronized benidipine WO2023113744A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2021019695 2021-12-13
TR2021/019695 TR2021019695A2 (en) 2021-12-13 A TABLET FORMULATION CONTAINING MICRONIZED BENIDIPINE

Publications (2)

Publication Number Publication Date
WO2023113744A2 true WO2023113744A2 (en) 2023-06-22
WO2023113744A3 WO2023113744A3 (en) 2023-08-03

Family

ID=86775370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2022/051468 WO2023113744A2 (en) 2021-12-13 2022-12-10 A tablet formulation comprising micronized benidipine

Country Status (1)

Country Link
WO (1) WO2023113744A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003104888A (en) * 2001-09-28 2003-04-09 Taiyo Yakuhin Kogyo Kk Tablet of dihydropyridine derivative
JP4606258B2 (en) * 2003-06-17 2011-01-05 協和発酵キリン株式会社 Pharmaceutical composition containing benidipine hydrochloride
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions

Also Published As

Publication number Publication date
WO2023113744A3 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
CA2592102C (en) Matrix type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same
US20060159753A1 (en) Matrix type sustained-release preparation containing basic drug or salt thereof
JP2008525313A (en) Anti-dementia drug stabilization method
JP2023175743A (en) Pharmaceutical composition containing poorly soluble basic drug
US20200061058A1 (en) Pharmaceutical formulation containing tadalafil
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
KR102082775B1 (en) Formulation with enhanced water solubility and bioavailability
JP7161176B2 (en) Orally disintegrating tablet and manufacturing method thereof
WO2023113744A2 (en) A tablet formulation comprising micronized benidipine
WO2013008253A2 (en) Imatinib formulations
WO2019192195A1 (en) Pharmaceutical composition containing dabigatran etexilate and preparation method thereof
WO2023113745A1 (en) A film coated tablet formulation comprising benidipine
US20100172982A1 (en) Sustained release formulations of divalproex sodium
WO2014115082A1 (en) Pharmaceutical formulations of imatinib
TR2021019695A2 (en) A TABLET FORMULATION CONTAINING MICRONIZED BENIDIPINE
TR2021019697A1 (en) A FILM-COATED TABLET FORMULATION CONTAINING BENIDIPINE
WO2020055359A2 (en) Oral dosage form of sorafenib tosylate
US20080182908A1 (en) Pharmaceutical compositions comprising memantine
EP4091604B1 (en) Granules containing posaconazole
JP6423034B2 (en) Imidafenacin-containing tablets
US20230390254A1 (en) Pharmaceutical compositions of ubrogepant and process for preparation thereof
WO2022162687A1 (en) Pharmaceutical compositions comprising nilotinib
WO2023195955A1 (en) A film coated tablet comprising selexi̇pag and its preparation process
WO2023195957A1 (en) A film coated tablet comprising selexi̇pag processed with wet granulation
WO2022173402A1 (en) A film coated tablet comprising naltrexone hydrochloride